Condition: Adjuvant Therapy · CDK4/6 Inhibitor · Sponsor: European Institute of Oncology
This is a multicenter observational study with both retrospective and prospective phase, designed to evaluate the clinico-pathologic characteristics and outcomes of patients with HR+/HER2- EBC at high risk of recurrence treated with ribociclib or abemaciclib in combination with ET in the adjuvant setting.
This description comes directly from the study's public registry record.
Nadia Bianco, MD · +39 02 94371977 · nadia.bianco@ieo.it
Always discuss trial participation with your own doctor first.
| ASST Papa Giovanni XXIII | Bergamo, Italy, Italy | Not Yet Recruiting |
| ASST Spedali Civili di Brescia | Brescia, Italy, Italy | Recruiting |
| P.O. Antonio Perrino - ASL Brindisi | Brindisi, Italy, Italy | Not Yet Recruiting |
| ASST Ospedale Maggiore di Crema | Crema, Italy, Italy | Recruiting |
| ASST Lecco - PO Alessandro Manzoni | Lecco, Italy, Italy | Not Yet Recruiting |
| Asst Ovest Milanese | Legnano, Italy, Italy | Not Yet Recruiting |
| IRCCS Ospedale San Raffaele | Milan, Italy, Italy | Recruiting |
| Fondazione IRCCS Istituto Nazionale dei Tumori di Milano | Milan, Italy, Italy | Not Yet Recruiting |
| European Institute of Oncology | Milan, Italy, Italy | Recruiting |
| PO Luigi Sacco - ASST Fatebenefratelli Sacco | Milan, Italy, Italy | Recruiting |
| Azienda Ospedaliero-Universitaria di Modena | Modena, Italy, Italy | Not Yet Recruiting |
| Fondazione IRCCS San Gerardo dei Tintori | Monza, Italy, Italy | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07180693